Anta Sports Expands Global Footprint With Strategic Puma Stake 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Amazon Explores AI Content Marketplace With Media Publishers 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
BURLINGTON, Mass., June 23, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been recognized as one of the The Boston Business Journal’s “Best Places to Work.” Flexion ranked 5th in the medium business category (100 to 249 employees) and was presented with the award at a ceremony held last night at Symphony Hall in Boston.
The Best Places to Work program honors leading employers from the greater Boston area for going “above and beyond” to create an exceptional work environment for their employees. Companies must have a physical office in Massachusetts and are judged based on the results of an employee survey evaluating: communication and resources, individual needs, manager effectiveness, personal engagement, team dynamics and trust in leadership.
Flexion’s mission is to advance transformative therapies that have the potential to make a meaningful difference for patients confronting musculoskeletal conditions. The company is distinguished by five core values that define its culture – focus, ingenuity, tenacity, transparency and fun. These values serve as the pillars upon which co-founders, Michael Clayman, M.D., President and Chief Executive Officer and Neil Bodick, M.D., Ph.D., Chief Scientific Officer, established and grew Flexion. In 2016, the company expanded from 50 to 100 employees, and it plans to reach approximately 250 people by the end of 2017.
“We have a remarkably talented team of people with deep expertise and unrivaled passion,” said Dr. Clayman. “From the outset, Neil and I appreciated the importance of attracting outstanding professionals who truly share our vision and want to be a part of a high-performing, respectful and collaborative organization. We have worked hard to create and foster a culture that values great ideas and gives everyone a voice. We are honored by this recognition and extend our sincere gratitude to our colleagues who live and breathe our core values and make Flexion such a fun place to work.”
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta™ (FX006), is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contact: Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected]
